Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 81.39 percent increase over losses of $(3.17) per share from the same period last year.
Related Posts
HC Wainwright & Co. Maintains Buy on AudioEye, Lowers Price Target to $17
HC Wainwright & Co. analyst Scott Buck maintains AudioEye (NASDAQ:AEYE) with a Buy and lowers the price target from $20 to $17.
Netflix Says It Has Ordered A ‘Stranger Things’ Spin-Off Series
https://twitter.com/netflix/status/1544731656170262528?s=20&t=x0UP2yt0fKBwPxjbgJQOGg
PowerSchool Announces Pricing Of Secondary Offering Of 8.7M Shares Of Class A Common Stock At A Price Of $21/Share By Selling Stockholders
PowerSchool Holdings, Inc. (NYSE:PWSC) ("PowerSchool"), the leading provider of cloud-based software for K-12 education in North America, today announced the pricing of an underwritten offering of 8,700,000